URBASON*IM EV 1F 250MG+1F 5ML ( DrugBank: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
222	Primary nephrotic syndrome	1

222. Primary nephrotic syndrome

Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-006115-59-IT (EUCTR)	11/06/2012	08/06/2012	A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)	A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) - GNM-2011	MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hyp MedDRA version: 14.1;Level: PT;Classification code 10018372;Term: Glomerulonephritis membranous;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Trade Name: MABTHERAEV 1FL 50ML 500MG Trade Name: URBASONIM EV 1F 250MG+1F 5ML Trade Name: MEDROL10CPR DIV 4MG Trade Name: ENDOXAN BAXTER50CPR RIV 50MG	AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy